The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Christine Chen(Princess Margaret Cancer Centre), Jennifer Gauvin(Research Triangle Park Foundation), Joanna Opalinska(GlaxoSmithKline (United States)), Rakesh Kumar(GlaxoSmithKline (United States)), Shannon R. Morris(Research Triangle Park Foundation), Simon J. Harrison(The University of Melbourne), Deborah A. Smith(Research Triangle Park Foundation), Sung‐Soo Yoon(Seoul National University), Richard A. Brigandi(GlaxoSmithKline (United States))
Cited by 140
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719